Valsartan

Valsartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for Diovan tablets (valsartan), lists three uses: treating high blood pressure in adults and children 1 year and older, reducing hospitalization for heart failure (NYHA class II-IV) in adults, and reducing cardiovascular deaths in clinically stable adults with left ventricular failure or dysfunction after a myocardial infarction. Diovan is the brand name on the label read.

Also called Diovan

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 69749; UNII 80M03YXJ7I. UNII 80M03YXJ7I is the UNII of the substance as the label names it. MeSH descriptor D000068756 is Valsartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Novartis Pharmaceuticals Corporation label for Diovan (valsartan) tablets, application NDA021283, effective 2026-08-11 in openFDA; Drugs@FDA lists the application's sponsor as NOVARTIS. Other valsartan labels, the Diovan HCT combination label and fixed-dose combination labels with other substances were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 24 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
24
Phase 3 or 4
21
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingEnrolling by invitationCompletedTerminatedUnknown statusAll statuses
Phase 2002013
Phase 31181112
Phase 4007029
All phases11171424

Conditions these trials study

And 5 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 11 more.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context Adults for whom the US label of valsartan (Diovan) lists an indication: hypertension, NYHA class II-IV heart failure, left ventricular failure or dysfunction after myocardial infarction

Recipient
Adult
Population
Adult patients described in the indications section of the label. The hypertension sentence also names children, who are recorded in a separate context.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the passages read state
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
  • Adult patients with hypertension
  • Adult patients with heart failure (NYHA class II-IV)
  • Clinically stable adult patients with left ventricular failure or left ventricular dysfunction following myocardial infarction
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults; and for the reduction of cardiovascular mortality in clinically stable adults with left ventricular failure or left ventricular dysfunction following myocardial infarction.

    Applies to Adult Adults for whom the US label of valsartan (Diovan) lists an indication: hypertension, NYHA class II-IV heart failure, left ventricular failure or dysfunction after myocardial infarction

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-08-11
      Source state
      Current
      Version fingerprint
      688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260811.
      Retrieved
      Source effective date
      2026-08-11
      Source state
      Current
      Version fingerprint
      688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA Drugs@FDA record for application NDA021283 (DIOVAN, sponsor NOVARTIS): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application NDA021283, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application NDA021283, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      a78049a0e3c8f2cb62336a0d03a25f1f483fb5af1df4497ffbd39f3710ee44ee
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

Context Children for whom the US label of valsartan (Diovan) lists hypertension as an indication: children 1 year and older

Recipient
Child
Population
Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Label wording: children 1 year and older
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Children with hypertension (children 1 year and older)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure, in children 1 year and older.

    Applies to Child Children for whom the US label of valsartan (Diovan) lists hypertension as an indication: children 1 year and older

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2026-08-11
      Source state
      Current
      Version fingerprint
      688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260811.
      Retrieved
      Source effective date
      2026-08-11
      Source state
      Current
      Version fingerprint
      688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In newborns, infants and children 1

Claims whose context is a newborn, an infant or a child.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure, in children 1 year and older.

    Applies to Child Children for whom the US label of valsartan (Diovan) lists hypertension as an indication: children 1 year and older

    Population, setting and follow-up
    • Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Label wording: children 1 year and older
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2026-08-11
      Source state
      Current
      Version fingerprint
      688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Diovan (valsartan) tablets, Novartis Pharmaceuticals Corporation label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 5ddba454-f3e6-43c2-a7a6-58365d297213 (manufacturer Novartis Pharmaceuticals Corporation, application NDA021283), returned on 2026-11-09. The label text is dated 2026-08-11 (effective_time). Other openFDA records of valsartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260811.
      Retrieved
      Source effective date
      2026-08-11
      Source state
      Current
      Version fingerprint
      688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.

BYVALSON

No label from the application holder was found in the openFDA label dataset for application NDA206302. This page does not show another labeler's label in its place.

DIOVAN

No label from the application holder was found in the openFDA label dataset for application NDA020665. This page does not show another labeler's label in its place.

DIOVAN

No label from the application holder was found in the openFDA label dataset for application NDA021283. This page does not show another labeler's label in its place.

DIOVAN HCT

No label from the application holder was found in the openFDA label dataset for application NDA020818. This page does not show another labeler's label in its place.

ENTRESTO SPRINKLE

Application
NDA218591
Labeler
Novartis Pharmaceuticals Corporation
Label version
Version 25, effective
Label set id
000dc81d-ab91-450c-8eae-8eb74e72296f
Boxed warning
Yes: WARNING: FETAL TOXICITY
Sections the label has
Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies

EXFORGE

No label from the application holder was found in the openFDA label dataset for application NDA021990. This page does not show another labeler's label in its place.

EXFORGE HCT

No label from the application holder was found in the openFDA label dataset for application NDA022314. This page does not show another labeler's label in its place.

PREXXARTAN

No label from the application holder was found in the openFDA label dataset for application NDA209139. This page does not show another labeler's label in its place.

VALTURNA

No label from the application holder was found in the openFDA label dataset for application NDA022217. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA020665 DIOVAN
  2. Approval NDA020818 DIOVAN HCT
  3. Approval NDA021283 DIOVAN
  4. Supplemental approval NDA021283 DIOVAN
  5. Supplemental approval NDA020665 DIOVAN
  6. Supplemental approval NDA021283 DIOVAN
  7. Supplemental approval NDA020818 DIOVAN HCT
  8. Supplemental approval NDA021283 DIOVAN
  9. Supplemental approval NDA020818 DIOVAN HCT
  10. Approval NDA021990 EXFORGE
  11. Supplemental approval NDA021283 DIOVAN
  12. Supplemental approval NDA021990 EXFORGE
  13. Supplemental approval NDA020818 DIOVAN HCT
  14. Approval NDA022314 EXFORGE HCT
  15. Approval NDA022217 VALTURNA
  16. Approval NDA206302 BYVALSON
  17. Approval NDA209139 PREXXARTAN
  18. Supplemental approval NDA021283 DIOVAN
  19. Approval NDA218591 ENTRESTO SPRINKLE

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 9

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA020665

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

    ProductNDA020818

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 5 efficacy supplement approvals on record.

    ProductNDA021283

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA021990

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022217

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022314

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA206302

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA209139

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA218591

Registry trials 24

Record details

Record id
cardio:valsartan
Content hash
fe2b710435b27ded9faa8be25db3ebef6b5fdbf8145db28011671a152b3fa124